BioTuesdays
Theratechnologies

FDA completes inspection of ibalizumab plant

Theratechnologies (TSX:TH) has been notified by its partner, TaiMed Biologics of Taiwan, that the FDA has completed the pre-license inspection of the WuXi Biologics facility, where Theratechnologies’ ibalizumab will be...

BioLight Life Sciences Ltd.

BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for...

Theratechnologies

Theratechnologies presents new HIV findings

Theratechnologies’ (TSX:TH) presented results on HIV susceptibility to ibalizumab from a Phase 2b trial, along with new findings for EGRIFTA (tesamorelin for injection), at the 9th IAS Conference on HIV Science in Paris...

Dimerix posts positive Phase 2a in CKD

Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200. Dimerix will now progress...

Scientus Pharma Logo

Scientus inks cannabis supply pact with Aphria

Closely-held Scientus Pharma, through its HydRx Farms unit, has entered into a major wholesale purchase agreement with Aphria (TSX:APH; OTCQB:APHQF). Under the accord, Aphria would supply more than 25,000 fully-grown...

Titan Pharmaceuticals Logo

Fortune hails Titan’s ProNeura technology

Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.” The article said Titan’s Probuphine implant for the treatment of...

Stryker to acquire Novadaq Technologies

Stryker (NYSE:SYK) has agreed to acquire Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) for $11.75 a share, implying a total equity value of approximately $701-million. The transaction price represents a premium of...

3D Signatures

3DS advances Hodgkin’s lymphoma test

The clinical trial component of 3D Signatures’ (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) validation program is under way. This process is referred to as Stage 3 of the validation program...

Blue Spark Technologies

Blue Spark gets U.S. patent notice for TempTraq

The U.S. Patent and Trademark Office issued a Notice of Allowance for closely held Blue Spark Technologies’ patent application referred to as, “body temperature logging patch,” or its brand name, TempTraq. The wearable...

Implandata Ophthalmic Products

Implandata EYEMATE receives CE Mark

Closely held Implandata Ophthalmic Products of Germany has received CE Mark for its EYEMATE system, making it available for commercial use within the EU. The EYEMATE system provides intraocular pressure (IOP) readings...

Quidel

Quidel acquires InflammaDry and AdenoPlus

Quidel (NASDAQ:QDEL) has acquired the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for about $14-million. InflammaDry is the only point-of-care test that detects elevated levels of MMP-9, a key...

Ortho Regenerative Technologies

BMJ article dovetails with Ortho RTi focus

An article in the latest issue of the weekly peer-reviewed journal, The BMJ, about arthroscopic surgery for degenerative knee arthritis and meniscal tears appears to dovetail with an approach by Ortho Regenerative...